At last a schedule For a while it seemed that they might be considering a switch to Sherri`s new super compound Os-4T but it was today explained that they are working up two indications together - with everything therefore taking twice as long - and that subject to this preclinical work being successful Rutherrin is scheduled to go into the Clinic in two major indications - one the biggest killer of all - in Q4 of next year.
Timing may prove providential and low level X-ray looks certain to be used to activate in at least one indication - possibly on a stand-alone basis.
Newsflow - most of it covid-proof - could build very nicely along the timelines of this schedule.
Continue to add at these levels.
Proposed Schedule
Compound: Rutherrin
Indications: Glioblastoma Multiforme and Non small-cell Lung Cancer.
Scheduled timetable
Q4 2020
Non GLP complete on one indication and continuing for another.
Q1 2021
Non-GLP for both indications to be completed.
Q2 2021
GLP for both indications to commence.
Q3 2021
GLP for both indications to be completed.
Q4 2021
Human trials to launch in both indications